Murine MHC class II locus control region drives expression of human beta-glucocerebrosidase in antigen presenting cells of transgenic mice.
Gaucher disease is the most prevalent lysosomal storage disorder in humans, resulting from an inherited deficiency of the enzyme glucocerebrosidase. Although the enzyme is ubiquitously expressed, cells of the reticuloendothelial system are particularly affected since they accumulate the undigested glucosylceramide substrate through their role in scavenging and breaking down cell debris. Gaucher disease is an attractive target for somatic gene therapy. To test the ability to express the enzyme in the affected cell types we have generated transgenic mice expressing human glucocerebrosidase under the control of the murine major histocompatibility complex (MHC) class II Ead locus control region (LCR). The four transgenic lines express the human enzyme in a copy number-dependent manner, independent of the integration site of the transgene. Over-expression of the human enzyme in mice did not result in any abnormal phenotype or pathology during the period of observation (> 2 years). The enzyme is expressed in B cells, monocytes, dendritic cells, thymic epithelial cells, and macrophages in various tissues: the peritoneal cavity, bone marrow, spleen, kidney, gastrointestinal tract, Kupffer cells in the liver and alveolar macrophages in lungs. Expression in the brain was limited to perivascular macrophages and was not seen in microglial cells. Therefore, the MHC class II LCR could potentially be of use in somatic gene therapy for type 1 Gaucher disease.
Guy
J
J
Department of Cell Biology and Genetics, Faculty of Medicine, Erasmus University Rotterdam, The Netherlands.
Willemsen
R
R
Langeveld
A
A
Grosveld
F
F
Drabek
D
D
D000818:Animals; D000938:Antigen-Presenting Cells / Q000201:enzymology*; D001853:Bone Marrow / Q000201:enzymology; D001921:Brain / Q000201:enzymology; D005776:Gaucher Disease / Q000201:enzymology / Q000276:immunology / Q000628:therapy*; D015870:Gene Expression; D005802:Genes, MHC Class II; D015316:Genetic Therapy / Q000379:methods*; D005962:Glucosylceramidase / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D007422:Intestines / Q000201:enzymology; D007668:Kidney / Q000201:enzymology; D008099:Liver / Q000201:enzymology; D019901:Locus Control Region; D008168:Lung / Q000201:enzymology; D008264:Macrophages / Q000201:enzymology; D051379:Mice; D008822:Mice, Transgenic; D013154:Spleen / Q000201:enzymology; D013950:Thymus Gland / Q000201:enzymology
D005962:Glucosylceramidase